Search results
Results from the WOW.Com Content Network
Buserelin, sold under the brand name Suprefact among others, is a medication which is used primarily in the treatment of prostate cancer and endometriosis. [3] [1] [2] It is also used for other indications such as the treatment of premenopausal breast cancer, uterine fibroids, and early puberty, in assisted reproduction for female infertility, and as a part of transgender hormone therapy.
Leuprorelin, also known as leuprolide, is a manufactured version of a hormone used to treat prostate cancer, breast cancer, endometriosis, uterine fibroids, for early puberty, or as part of transgender hormone therapy. [10] [11] It is given by injection into a muscle or under the skin. [10]
Gonadotropin-releasing hormone antagonists (GnRH antagonists) are a class of medications that antagonize the gonadotropin-releasing hormone receptor (GnRH receptor) and thus the action of gonadotropin-releasing hormone (GnRH).
A gonadotropin-releasing hormone agonist (GnRH agonist) is a type of medication which affects gonadotropins and sex hormones. [1] They are used for a variety of indications including in fertility medicine and to lower sex hormone levels in the treatment of hormone-sensitive cancers such as prostate cancer and breast cancer, certain gynecological disorders like heavy periods and endometriosis ...
Following the review, the government banned the prescription of puberty-suppressing hormones to under 18s. NHS England also announced a review into the operation of adult gender dysphoria clinics ...
A gonadotropin-releasing hormone antagonist (GnRH antagonist) is a GnRH modulator that blocks the GnRH receptor resulting in an immediate drop in gonadotropin (FSH, LH) secretion. GnRH antagonists are primarily used in IVF treatments to block natural ovulation.
Nafarelin is a gonadotropin-releasing hormone agonist (GnRH agonist) and works by preventing the production of sex hormones by the gonads. [1] [2] It can lower sex hormone levels by 95% in both sexes. [1] [2] Nafarelin is a peptide and an analogue of GnRH Tooltip gonadotropin-releasing hormone. [8] Nafarelin was introduced for medical use in 1990.
MUSC says it stopped providing transgender pediatric hormonal therapy in July after the S.C. Legislature passed a one-year law banning state money from being used to provide gender transition care ...